HIV lipodystrophy: a review.
HIV lipodystrophy: a review.
复制标题
DOI：
10.1310/3hhb-59up-93mm-aaxy
复制
发表时间：
2000-11-01
影响因子：
--
通讯作者：
Kravcik, S
中科院分区：
文献类型：
--
作者：
Kravcik, S
高度有效的抗逆转录病毒治疗的显著临床益处在一定程度上被不可预见的长期毒性的发展所抵消。其中，HIV脂肪营养不良综合征最为突出。一系列相关但可能独立的表现包括脂肪沉积和萎缩以及代谢并发症，如高脂血症和糖尿病。这些都归因于使用了蛋白酶抑制剂，但也可能涉及其他因素，特别是核苷逆转录酶抑制剂的使用，特别是司他夫定。该综合征的任何一种表现的发病机制仍有待解释。新陈代谢并发症可能对标准治疗有反应，但大多数针对脂肪变化的治疗都不成功。本综述将对该领域的知识状况进行总结。
The dramatic clinical benefit of highly active antiretroviral therapy has been offset, to an extent, by the development of unforeseen long-term toxicities. Of these, the HIV lipodystrophy syndrome is most prominent. The array of related but possibly separate manifestations includes fat deposition and atrophy and metabolic complications such as hyperlipidemias and diabetes mellitus. These have been attributed to the use of protease inhibitors, but other factors may be involved, particularly the use of nucleoside reverse transcriptase inhibitors, especially stavudine. The pathogenesis of any of the manifestations of the syndrome remains to be explained. The metabolic complications may respond to standard treatments, but most therapies directed at fat changes have been unsuccessful. This review will summarize the state of knowledge in the field.